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Summary
 
We previously generated a panel of T helper cell 1 (Th1) clones specific for an encephalito-
genic peptide of myelin proteolipid protein (PLP) peptide 139–151 (HSLGKWLGHPDKF)
that induces experimental autoimmune encephalomyelitis (EAE) upon adoptive transfer. In
spite of the differences in their T cell receptor (TCR) gene usage, all these Th1 clones required
W144 as the primary and most critical TCR contact residue for the activation. In this study,
we determined the TCR contact residues of a panel of Th2/Th0 clones specific for the PLP
peptide 139–151 generated either by immunization with the PLP 139–151 peptide with anti–
B7-1 antibody or by immunization with an altered peptide Q144. Using alanine-substituted
peptide analogues of the native PLP peptide, we show that the Th2 clones have shifted their
primary contact residue to the NH
 
2
 
-terminal end of the peptide. These Th2 cells do not show
any dependence on the W144, but show a critical requirement for L141/G142 as their major
TCR contact residue. Thus, in contrast with the Th1 clones that did not proliferate to A144-
substituted peptide, the Th2 clones tolerated a substitution at position 144 and proliferated to
A144 peptide. This alternative A144 reactive repertoire appears to have a critical role in the
regulation of autoimmune response to PLP 139–151 because preimmunization with A144 to
expand the L141/G142-reactive repertoire protects mice from developing EAE induced with
the native PLP 139–151 peptide. These data suggest that a balance between two different T
cell repertoires specific for same autoantigenic epitope can determine disease phenotype, i.e.,
resistance or susceptibility to an autoimmune disease.
 
E
 
xperimental autoimmune encephalomyelitis (EAE)
 
1
 
, is
an example of an organ-specific autoimmune disease
that can be induced in experimental animals by immuniza-
tion with several different myelin proteins, including mye-
lin basic protein (MBP) and myelin proteolipid protein
(PLP). EAE is mediated by myelin antigen-reactive helper
T cells because elimination of MBP reactive Ly1
 
1
 
, but not
Ly2
 
1
 
, cells prevents transfer of EAE (1, 2), and monoclonal
antibodies specific for CD4 can inhibit and/or reverse on-
going disease (3, 4). Direct evidence for the role of CD4
 
1
 
T cells in EAE induction has come from adoptive transfer
studies in which MBP- and PLP-reactive CD4
 
1
 
 T cell
lines or clones were shown to induce chronic relapsing en-
cephalomyelitis and paralysis after transfer (2, 5, 6).
Subpopulations of CD4
 
1
 
 helper T cells (Th) produce
distinct patterns of cytokines, and this has led to the con-
cept of functional heterogeneity among Th cells (7, 8).
Upon antigenic stimulation, naive CD4
 
1
 
 T cells (Th pre-
cursor cells) differentiate into at least two populations: Th1
and Th2. Th1 produce IL-2 and/or IFN-
 
g
 
, elicit delayed
type hypersensitivity (DTH) responses, activate macro-
phages, and have been implicated in inducing tissue injury
in many organ-specific autoimmune diseases. Th2, on the
other hand, produce IL-4, IL-5, and IL-10, are especially
important for IgE production and eosinophilic inflamma-
tion, and may suppress cell-mediated immunity. Different
roles of these two subsets of Th in various immunopatho-
logical conditions like leprosy, leishmaniasis, and schistoso-
miasis, has been demonstrated (9–11). All encephalitogenic
T cell clones examined thus far have been of the Th1 type
 
1
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(12, 13). In contrast, the transfer of myelin antigen-reactive
Th2 cells do not induce disease, and in some cases, have
been shown to transfer protection against EAE (14–16).
Immunization of SJL mice with the encephalitogenic
PLP peptide 139–151 leads to the generation of Th1 cells,
and these clones recognize tryptophan in the center of the
peptide (W144) as the primary TCR contact residue (17).
The initial observation that the PLP 139–151-specific en-
cephalitogenic Th1 clones require W144 as the primary
TCR contact residue and most critical residue for activa-
tion has now been confirmed by three other laboratories
(18–20). We recently generated a panel of Th2/Th0 clones/
lines specific for PLP 139–151 and transfer of these Th2
clones both prevented and reversed PLP 139–151-induced
EAE (15, 16). Preimmunization with the altered peptide
Q144 prevents development of EAE and transfer of T cell
lines specific for the Q144 peptide confers protection
against EAE induced with the native PLP 139–151 peptide.
In analyzing the cellular basis for this protection, we gener-
ated T cell clones from the Q144-specific line. These
clones have two important properties: they (
 
a
 
) produce
Th2/Th0 cytokines and (
 
b
 
) they cross-react with the native
PLP 139–151 peptide (21). The PLP 139–151-specific Th2
clones included in this study were generated in three differ-
ent ways. SJL mice were first immunized with PLP 139–
151 and were injected simultaneously with anti-B7-1 anti-
body. For the second set of clones mice were immunized
with an altered form of the encephalitogenic peptide 139–
151 in which the primary TCR contact residue was
changed from tryptophan (W) to glutamine (Q) at position
144, and T cell clones were propagated with Q144 peptide
in culture. In a third independent T cell cloning, SJL mice
were immunized with Q144, and T cell clones were prop-
agated with the native peptide in vitro. Thus, we cloned al-
tered peptide-specific Th2 clones from Q144 immunized
mice from two independent lines. In one case, Q144 pep-
tide was used (Q1 clones), and in the second case, native
peptide W144 (QW clones) for in vitro propagation and as
the cognate ligands. In this study, we determined the fine
epitope recognition of the panel of Th2/Th0 clones and
compared it with a panel of encephalitogenic Th1 clones,
both of which react with the PLP peptide 139–151. The
data presented here show that in contrast with Th1 clones,
Th2 clones have shifted their primary TCR contact residue
to the NH
 
2
 
-terminal end of the peptide. This difference in
the fine epitopic recognition of encephalitogenic and pro-
tective repertoire has been exploited to regulate EAE.
 
Materials and Methods
 
Antigens.
 
PLP 139–151 (HSLGKWLGHPDKF) peptide, al-
tered Q144 peptide (HSLGKQLGHPDKF), and alanine-substi-
tuted peptides on the native backbone were synthesized in the
laboratory of Dr. R. Laursen (Boston University, Boston, MA)
using FMOC chemistry on a Milligen synthesizer (model 9050;
PerSeptive Biosystems, Framingham, MA). The control peptide
PLP 43–64 (EKLIETYFSKNYQDYEYLINVI) was synthesized by
Dr. D. Teplow (Brigham and Women’s Hospital, Boston, MA).
An I-A
 
s
 
–binding peptide ADLIAYLKAQTAK of PCC 81–104
(synthesized by Quality Controlled Biochemicals,, Hopkinton,
MA) was used as a control in some of the experiments.
 
T Cell Clones and Hybridomas.
 
The generation of PLP 139–
151-specific Th1 (13) and Th2 (15) clones has been described. In
brief, the Th1 clones were generated from the lymph nodes of
SJL mice after immunization with the PLP peptide 139–151 in
CFA (Difco, Detroit, MI). The lymph node cells were obtained
7–10 d after immunization, activated with PLP 139–151 peptide,
and propagated in the presence of IL-2 as described previously
(15). For the epitope analysis of the Th1 clones, T cell hybrido-
mas were also generated by the fusion of Th1 clones with
TCR
 
a
 
2
 
b
 
2
 
 BW1100 (17, 22). The hybridomas and the parent
Th1 clones expressed identical TCRs and showed similar fine an-
tigenic specificities.
Generation of Th2 clones specific for the PLP 139–151 pep-
tide by conventional techniques have met with limited success.
We generated PLP 139–151, reactive Th2 clones by three differ-
ent techniques. In the first attempt, the PLP 139–151-specific
Th2 clones were generated by immunizing SJL mice with the
PLP peptide 139–151, followed by intraperitoneal administration
of monoclonal anti-B7-1 antibody (15). Except for the anti-B7-1
administration in vivo, the PLP 139–151-specific Th2 clones
were expanded and propagated like the Th1 clones described
above (15). A control Th1 clone was derived the same way by
administration of control hamster Ig.
The second and third independent panels of PLP 139–151-
reactive Th2/Th0 clones were generated by immunizing SJL
mice with the altered peptide Q144 in CFA (16) on separate oc-
casions. In one case, lymph node cells from Q144-immunized
SJL mice were propagated in culture with Q144 peptide, whereas
in the other case, the lymph node cells were propagated with the
native peptide. The lymph node cells were activated with the
Q144 peptide and maintained in DMEM containing 0.6% T cell
growth factor (T-STIM; Collaborative Biomedical Research, Bed-
ford, MA) and 0.06% recombinant IL-2. Q144-reactive T cell
lines were shown to mediate protection against EAE upon adop-
tive transfer (16). All the clones were fed every 2–3 d and stimu-
lated with the immunizing antigen (20 
 
m
 
g/ml) plus irradiated SJL
spleen cells as a source of APC every 3–4 wk. In a third attempt,
PLP 139–151-reactive Th2 clones were generated by immuniz-
ing SJL mice with the altered peptide Q144 as described above,
but the lymph node cells were activated with the native PLP
139–151 peptide in vitro to expand T cell clones that are cross-
reactive with the native peptide. In total, 10 Th2/Th0 clones,
generated by three different clonings that react with the PLP
139–151, were included in the study.
 
Activation of T Cell Clones and Hybridomas.
 
T cell clones or hy-
bridomas (5 
 
3
 
 10
 
4
 
) were cultured in triplicate in 96-well plates
with 5 
 
3
 
 10
 
5
 
 irradiated SJL spleen cells and various concentra-
tions of synthetic peptides in a final volume of 0.2 ml. After 24 h,
0.1 ml of the supernatant from the hybridomas was transferred to
96-well flat-bottomed plates to which 10
 
4
 
 HT-2 (IL-2/IL-4–
dependent) cells were added. The ability of HT-2 cells to prolif-
erate was determined by thymidine incorporation. The plates
with T cell clones were incubated for 48 h at 37
 
8
 
C and then
pulsed with [
 
3
 
H]thymidine for 16–18 h, after which they were
harvested and the mean thymidine incorporation in triplicate
wells was calculated. The [
 
3
 
H]thymidine incorporation was de-
termined in a scintillation counter (model LS 5000; Beckman
Instrs., Fullerton, CA). The data are presented as mean cpm in-
corporated into triplicate wells.
To compare the effects of a particular substitution on T cell 
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proliferation and to make data readily comparable, the data has
also been presented as percentage of control, in which case the
mean T cell proliferation with the cognate antigen (native pep-
tide) was taken as 100% and response to the substituted peptide
was expressed as percent response of the cognate antigen (percent
control). Proliferation of 
 
.
 
10% of the native peptide is taken as
positive.
 
In Vitro Proliferation Assays.
 
Mice were injected subcutane-
ously at five sites with antigen emulsified in CFA (Difco) contain-
ing a total of 250 
 
m
 
g 
 
Myobacterium tuberculosis
 
 H37 RA. Mice im-
munized with a single peptide received a total of 100 
 
m
 
g of
antigen (native PLP 139–151 or A144) or a mixture of these two
peptides. On day 10, lymph nodes were removed and LNC pre-
pared from them. LNC (4 
 
3
 
 10
 
5
 
/well) were cultured in triplicate
in 96-well round-bottomed plates (Falcon, Becton Dickinson, Lin-
coln Park, NJ), in the presence of antigen, for 48 h and then
[
 
3
 
H]thymidine (1 
 
m
 
Ci/well) was added for the last 16 h before
harvesting the cells. The [
 
3
 
H]thymidine incorporation was deter-
mined in a scintillation counter (model LS 5000; Beckman Instr.).
Supernatants from the lymph node cells activated with antigenic
peptides were harvested at 40 h for determining the type and
amount of cytokines accumulated in the culture supernatant.
 
Cytokine ELISA.
 
T cell clones were activated with syngeneic
spleen cells as APCs and 50 
 
m
 
g/ml of antigen. Supernatants were
harvested 48 h later and tested for the presence of cytokines by
ELISA as described (15). IL-2, IL-4, and IL-10 ELISA compo-
nents (antibodies and cytokine standards) were obtained from
PharMingen (San Diego, CA). In brief, ELISA plates were coated
with purified rat mAb to mouse IL-2 (clone JES6-1A12), IL-4
(clone BVD4-1D11), and IL-10 (clone JES5-2A5). Biotinylated
rat mAb to mouse IL-2 (clone JES5H4), IL-4 (BVD6-24G2), and
IL-10 (SXC-1) were used as secondary detecting antibodies. IFN-
 
g
 
ELISA components were obtained from Genzyme (Cambridge,
MA). Monoclonal hamster anti–mouse IFN-
 
g
 
 was used as the
primary antibody; polyclonal goat anti–mouse IFN-
 
g
 
 was the
secondary antibody. Assays were developed with TMB Micro-
well peroxidase substrate (Kirkegaard and Perry Labs., Inc.,
Gaithersburg, MD) and read after the addition of stop solution at
450 nm using a model 3550 Microplate Reader (BioRad Labs.,
Hercules, CA).
 
In Vivo Treatment with PLP 139-151 Analogues.
 
SJL mice ob-
tained from Jackson Labs. (Bar Harbor, ME) were pretreated with
100 
 
m
 
g of each of the following peptide analogues in 100 
 
m
 
g
CFA: A141, A142, A144, A147, and native W144. After 1 wk,
these mice were immunized with 50 
 
m
 
g of the native PLP 139–
151 peptide (W144) and pertussis vaccine as described (15). Mice
were observed regularly for signs of disease. Clinical course of the
disease is scored as follows: 1, tail atony; 2, hind limb weakness; 3,
hind limb paralysis; 4, paralysis of all four limbs; 5, moribund.
 
Results
 
Cytokine Profile of PLP 139–151-specific T Cell Clones.
 
We previously generated a panel of T cell clones specific
for PLP 139–151 peptide, of which five clones (2E5, 4E3,
5B6, 7A5, and SPL1.1) were tested in detail for epitope
specificity (17), cytokine production (13), and ability to
transfer EAE (6) upon adoptive transfer. All of these clones
were of the Th1 phenotype in that they produced IFN-
 
g
 
,
but not IL-4 or IL-10, upon activation with the PLP 139–
151 peptide (13). The structure of the epitope recognized
by the T cell clones was defined, and all of them showed a
critical requirement for W144 in the center of the peptide
as a TCR contact residue for activation (17). The finding
that the encephalitogenic PLP 139–151-specific Th1 clones
require W144 as the primary and the most critical TCR
contact residue for activation has since been confirmed by
other groups (18–20). We subsequently generated a panel
of T cell clones by immunization with PLP 139–151 pep-
tide by administration of anti-B7-1 antibody in vivo, and
upon cytokine analysis, the vast majority of these clones
turned out to be of the Th2 phenotype. We have now an-
alyzed in detail the cytokine production and epitope speci-
ficity of four of the clones (1E3, 1E6, 1E10, and 1A8) gen-
erated with anti–B7-1 antibody treatment in vivo. As a
control, we also used a T cell clone (1D9) that was gener-
ated in parallel by immunization of SJL mice with PLP
139–151, followed by administration of hamster Ig in vivo
(15). In a third cloning, we generated PLP 139–151-reac-
tive Th2/Th0 clones by immunizing SJL mice with the al-
tered peptide Q144. Q144 altered peptide induces PLP
139–151-reactive Th2/Th0 cells, which mediate protec-
tion upon adoptive transfer. Three T cell clones (Q1.1B6,
Q1.3F4, and Q1.4A11) that showed stable growth in cul-
ture were included in the study and compared with other
PLP 139–151-reactive Th1 or Th2 clones. In a fourth in-
dependent T cell cloning, we generated Th2 clones by im-
munizing mice with Q144 altered peptide and the lymph
node cells from the immunized mice were activated with
the native peptide 139–151 to expand only the native pep-
tide cross-reactive clones. Three clones from this cloning
(QW.1D4, QW.6D10, and QW.9E1) were included in
this study. Thus, 10 PLP 139–151-reactive Th2/Th0 clones
generated by three independent cloning attempts were in-
cluded in this study.
The cytokine profile of the panel of 139–151-reactive T
cell clones is shown in Table 1. The 1D9 T cell clone pro-
duced large amounts of IFN-
 
g
 
 (
 
.
 
5 ng) and small amounts of
IL-10 (
 
,
 
1 ng) upon activation with PLP 139–151. The
clones 1E3, 1E6, 1E10, and 1A8 that were generated after
immunization with PLP 139–151 together with the anti-B7-1
in vivo showed a typical Th2 phenotype, in that they pro-
duced large amounts of both IL-4 and IL-10. The only ex-
ception was that the clone 1E6 produced only IL-10, and
not IL-4, after activation. The PLP 139–151-reactive T cell
clones generated after immunization with Q144 and in
vitro propagation with the Q144 peptide demonstrated a
mixed cytokine profile of Th0 and Th2 cytokines when ac-
tivated with the cognate antigen Q144. The clone Q1.1B6
(Th0) produced IL-4 and IFN-
 
g
 
 together; clone Q1.3F4 pro-
duced IL-4 (with low levels of IFN-
 
g
 
), whereas Q1.4A11
clone produced both IL-4 and IL-10 together with IFN-
 
g
 
 in
some experiments. The three clones (QW.1D4, QW.6D10,
and QW.9E1) generated by immunization with Q144 pep-
tide followed by in vitro propagation with the native PLP
peptide 139–151 showed a typical Th2 cytokine profile in
that they produced both IL-4 and IL-10 together except
for clone QW.1D4, which also produced small amounts of
IFN-
 
g
 
 (Table 1). 
To compare further MHC and CD4 requirements of the 
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PLP-specific Th1 and Th2 clones, we added mAbs specific
for I-A
 
s
 
 and CD4. Like the PLP 139–151-specific Th1
clones (13), the antigen-specific proliferative response of all
clones was blocked significantly by addition of an antibody
to I-A
 
s
 
 (10.2.16), but not by a control anti-I-E
 
k
 
 antibody
(14-4-4S), suggesting that the clones recognize the antigen
in the context of I-A
 
s
 
. Furthermore, the addition of anti-
CD4 antibody (GK 1.5) inhibited the proliferative re-
sponses of all the clones tested (data not shown). These data
demonstrate that, like the Th1 clones, the Th2 clones re-
quire I-A
 
s
 
 and CD4 for activation.
 
Antigen Specificity and Cross-reactivity of the PLP 139–151-
specific Th1 and Th2 Clones.
 
The PLP 139–151-specific Th1
(2E5, 4E3, 1D9, and SPL 1.1) and Th2 (1E3, 1E6, 1E10,
and 1A8), and three Th2/Th0 (Q1.1B6, Q1.3F4, and
Q1.4 A11) clones generated by immunization with Q144
peptide were tested for their antigen specificity to the cog-
nate ligands (PLP 139–151 or Q144) in an in vitro prolifer-
ation assay. In addition, the A144 peptide was included in
the assay because our previous data showed an absolute re-
quirement for W at position 144 for the activation of all
Th1 clones and substitution of W at position 144 with any
other residue including A144 resulted in a peptide that did
not activate Th1 clones. The PLP peptide 43–64 was used
as a negative control peptide in these experiments. The
Th1 cells (1D9, 2E5, 4E3, and 5B6) demonstrated specific
proliferation only to PLP 139–151 and did not respond to
the altered peptides A144 or Q144, confirming a strict re-
quirement for W at position 144 for activation of Th1 cells
(Fig. 1). The Th2 clones (1E3, 1E6, 1E10, and 1A8) also
demonstrated specific proliferative responses to the PLP
139–151 peptide. However, in contrast with PLP 139–
151-specific Th1 clones, when A144 was used as the anti-
gen in the proliferation assay, all the Th2 clones responded
with varying levels of proliferation. In addition, the Th2
clone 1A8 also showed a significant proliferative response
to Q144. These data demonstrate that the PLP 139–151-
specific Th2 clones do not have an absolute requirement
for W144 for activation (Fig. 1). The group of PLP 139–
151-reactive Th2/Th0 clones generated by immunization
with Q144 peptide tested similarly in the proliferative assay
showed even greater degeneracy in their antigen recogni-
tion in that they showed a significant proliferative response
to the cognate antigen (Q144) and the native PLP peptide
139–151, but also showed a significant proliferative re-
sponse to A144 peptide (Fig. 1). It was interesting to note
that reactivity pattern of some of the clones generated by
PLP 139–151 plus anti-B7-1 antibody administration ap-
peared similar to the clones generated by Q144 immuniza-
tion (compare 1A8 with Q1.1B6). These data demonstrate
that unlike Th1 clones, the Th2 clones do not have a criti-
cal requirement for W at position 144, because they all re-
spond to A144.
 
Determination of Critical Residues for Activation of the Th1
and Th2 Clones.
 
Because the PLP 139–151-specific Th1
and Th2 clones showed a difference in proliferative re-
sponses when position 144 peptide-substituted analogues
(Q144 and A144) were used, the question was raised of
whether PLP 139–151-specific Th1 and Th2 clones recog-
nize the PLP 139–151 peptide differently. To address this
issue, we tested the PLP 139–151-specific Th1 and Th2
clones with a panel of peptides synthesized with alanine
substitutions at each residue on the PLP 139–151 backbone
at concentrations of 0.1–100 
 
m
 
g/ml in a proliferative assay.
Maximal T cell responses were generally achieved between
10–100 
 
m
 
g/ml of the antigen, and only the maximal T cell
 
Table 1.
 
Cytokine Profile of PLP 139–151-specific Th1 and Th2 Clones
 
Cytokine concentration
Clone Antigen Antibody treatment T helper phenotype IL-2 IFN-
 
g
 
IL-4 IL-10
 
D
 
 pg/ml
 
ID9 PLP 139–151 Hamster Ig Th1
 
,
 
80
 
.
 
5,000
 
,
 
80 840
1E3 PLP 139–151 Anti-B7-1 Th2
 
,
 
80
 
,
 
80
 
.
 
5,000
 
.
 
5,000
1E6 PLP 139–151 Anti-B7-1 Th2
 
,
 
80
 
,
 
80 200
 
.
 
5,000
1E10 PLP 139–151 Anti-B7-1 Th2
 
,
 
80
 
,
 
80 3,430
 
.
 
5,000
1A8 PLP 139–151 Anti-B7-1 Th2
 
,
 
80
 
,
 
80 2,400 2,380
Q1.1B6 Q144 None Th0
 
,
 
80 1,770 1,260
 
,
 
100
Q1.3F4 Q144 None Th0 220 580 1,090
 
,
 
100
Q1.4A11 Q144 None Th2 150 320 650 2,890
QW.1D4 PLP 139–151 None Th2
 
,
 
80 260 1,330 2,590
QW.6D10 PLP 139–151 None Th2
 
,
 
80
 
,
 
80 740 400
QW.9E1 PLP 139–151 None Th2 240
 
,
 
80 910 640
T cell clones were generated by immunization of SJL mice with PLP 139–151 in the presence of anti–B7-1 or control hamster Ig, or by immuniza-
tion with Q144. The clones were activated with peptide (50
 
m
 
g/ml) and syngeneic APCs. Culture supernatants were collected 48 h after activation
and tested by cytokine ELISA. The upper limit of detection in these assays was 5,000 pg/ml. The lower limit of detection was 80 pg/ml. 
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responses at a single dose are shown (Fig. 2). The panel of
Th1 clones reacted well to the native peptide, and various
different clones were sensitive to alanine substitutions at
positions 141, 142, 143, 144, and 147 (Fig. 2 
 
a
 
). In agree-
ment with our previous results (17) and that of others (18–
20), only W at position 144 was absolutely required for the
activation of Th1 clones in that an alanine substitution at
position 144 in the PLP peptide 139–151 led to abrogation
of T cell proliferation of all the Th1 clones tested, includ-
ing the newly derived Th1 clone 1D9. Histidine at position
147 and lysine at position 143 appear to be essential for
three of the four Th1 clones, whereas two of the four Th1
clones had a requirement for L141 and G142 (Fig. 2 
 
a
 
).
Epitopic analysis of Th2 clones specific for PLP peptide
139–151 with the panel of alanine substituted peptides is
shown in Fig. 2 
 
b.
 
 The clones 1E3, 1E6, and 1E10 showed
a decrease or a complete loss of reactivity when residues at
positions 141, 142, and 143 were substituted with alanine
in the native peptide. Clone 1A8 also failed to proliferate
when alanine substitutions were made at positions 146,
147, and 148. In contrast with the Th1 clones, all Th2
clones showed significant reactivity to the A144 peptide
(Fig. 2 
 
b
 
). The cumulative data with the four Th2 clones
suggest that alanine substitution at position 142 completely
abrogated responses to the peptide in all four clones tested,
and an alanine substitution at position at 141 was not toler-
ated by three of the four clones.
The T cell clones generated by immunization with the
altered peptide Q144 are generally of Th2/Th0 phenotype,
and besides recognizing Q144 peptide, these clones cross-
react with the native PLP 139–151 peptide (see Fig. 1). Be-
cause the Th2 clones specific for the PLP 139–151 show an
epitope shift, it was of interest to determine whether PLP
139–151-reactive T cell clones generated by immunization
with Q144 peptide show a similar epitope shift, which may
explain both cross-reactivity with the native peptide and
the Th2 phenotype. To address this issue, we tested the
panels of alanine-substituted peptides in the native PLP
139–151 backbone (Fig. 2 
 
c
 
). Clone Q1.1B6 has a require-
ment for residues 141, 143, and 147. Clone Q1.4A11 was
Figure 1. In vitro proliferative response of PLP peptide 139–151-spe-
cific Th1 and Th2 clones to the native PLP 139–151 (W144) and peptide
analogs that were substituted at position 144 with glutamine (Q144) and
alanine (A144). PLP 43–64 was used as a control antigen. The T cell
clones were incubated with the syngeneic spleen cells as APCs with vari-
ous concentrations of the peptides and 1 mCi of [3H]thymidine was added
during last 16–18 h of incubation. The data represent the mean CPM in-
corporated into insoluble DNA of triplicate wells. The standard devia-
tions were ,20%.
Figure 2. Proliferative responses of (a) Th1-, (b) Th2-, (c) Q1-reactive
Th2/Th0 clones, and (d) QW-reactive Th2/Th0 clones to the PLP pep-
tide 139–151, and panel of alanine-substituted peptides each position.
The ability of each substituted peptide to induce proliferation was com-
pared with that of the native peptide and the results expressed as the per-
centage of the response relative to the native peptide. Values are represen-
tative of 3–5 experiments. Maximal responses were obtained at peptide
concentrations of either 10 or 100 mM.872 Th1 and Th2 Clones Recognize the Same Peptide Differently
not activated when substitutions were made at residues
140, 141, 142, 143, 145, 146, and 147. Q1.3F4 needed res-
idues 141, 142, 143, 145, and 148 for activation. Similar to
the Th2 clones described above, these clones also did not
need W144 or Q144 for activation. However, the cumula-
tive data suggested that Q144-specific T cell clones re-
quired residues 141 and 143 for activation, because alanine
substitutions at these positions completely abrogated T cell
activation of all the three clones. Glycine at position 142
and histidine at position 147 was critical for the activation
of two out of three clones. The analysis of the third inde-
pendent set of Th2 clones generated by immunization with
the altered peptide Q144 and in vitro propagation with the
native peptide also showed a pattern very similar to the
Th2 clones described above (Fig. 2 d). Using alanine substi-
tutions in the native peptide backbone, it was clear that this
set of Th2 clones also did not show any critical require-
ment for W144, in that alanine substitution at this position
induced significant proliferation of the clones. However,
alanine substitution at positions 141 and 147 completely in-
hibited T cell proliferation in all the three clones and addi-
tional inhibitory effects were also seen by alanine substitu-
tion at positions 142, 143, and 146 for this set of Th2
clones. The analysis of fine epitopic specificity of the PLP
139–151-reactive Th1 versus Th2/Th0 clones, therefore,
show striking differences in the requirement for critical res-
idues for activation; while W144 is the primary and critical
residue for the activation of all the Th1 clones, the Th2/
Th0 clones do not need W144 for activation.
Using several different strategies to identify I-As binding
residues in the PLP 139–151 peptide (17), we found that
leucine at position 145 and proline at position 148 are the
major anchor residues for binding to I-As.
Structure of the PLP 139–151 Peptide Recognized by the
Th1 and Th2 Clones. From the cumulative data, using the
panel of alanine-substituted peptide analogues to identify
the structure of PLP 139–151 recognized by Th1 and Th2/
Th0 clones, it appears that the two subsets differ signifi-
cantly in their recognition of PLP 139–151 peptide. The
epitope recognition data of the Th1 clones is consistent
with our previous data (17) and those of three other inde-
pendent laboratories (18–20). The data of the Th2/Th0
clones is based upon three different clonings and the gener-
ation of PLP 139–151-specific Th2/Th0 cells by different
techniques. The responses of 4 PLP 139–151-specific Th1
clones and 10 Th2/Th0 clones to alanine-substituted pep-
tides in the native peptide backbone is summarized in Fig.
3 a. The most striking difference is that all 4 Th1 clones re-
quire W144 for T cell activation, and an alanine substitu-
tion at this position completely abrogates the response. In
contrast, all 10 Th2/Th0 clones showed a significant re-
sponse to the A144 peptide, demonstrating that these
clones do not require W144 as the primary contact residue.
In the case of Th1 clones, W144 is the major TCR contact
residue, and K143 and/or H147 the secondary TCR con-
tact residues. L141/G142 are minor TCR-binding residues
for the Th1 clones. 9 out of 10 Th2/Th0 clones seem to
require L141, and 7 of 10 clones require G142 for activa-
tion; thus, the emphasis for the primary TCR contacts has
been shifted to the NH2-terminal end of the peptide (Fig. 3
b). Although 9 out of 10 Th0/Th2 clones require leucine
at position 141, alanine at this position does activate some
Th2 clones. Like the Th1 clones, these Th2 clones also ap-
pear to have a minor requirement for the residues K143
and H147. From these data, it appears that the Th2/Th0-
reactive clones, generated by three different techniques, all
do not require W144 for activation, but mostly seem to re-
quire L141/G142 for their activation. However, neither of
the two residues (L141 or G142) appear to be absolutely
critical for the clones tested. Furthermore, there appears to
be subtle differences among the Th2 clones generated by
the three techniques: anti–B7-1–derived clones show main
emphasis on residues 142 and 141, Q144-specific clones re-
quire residues 141 and 143 with a minor requirement for
142 and 147 residues, and QW clones require 141 and 147.
Unlike Th1 clones where W144 is absolutely required, ala-
nine substitution at the position 141 or 142 does not lead to
complete abrogation of PLP 139–151-reactive Th2 responses.
Effect of Preimmunization with A144 Analogue on EAE.
Because encephalitogenic Th1 and protective Th2 cells
Figure 3. (a) Relative requirement of each residue in T cell activation
and (b) structure of PLP 139–151 recognized by PLP 139–151-reactive
Th1 and Th2/Th0 clones. This figure was compiled taking a proliferation
of greater than 10% that of the cognate ligand as positive.873 Prabhu Das et al.
show a dramatic difference in activation with A144 peptide
in that A144 peptide activates PLP 139–151-specific Th2
clones but not the Th1 clones, we tested the effect of pre-
immunization with A144 peptide on the induction of
EAE. Groups of SJL mice were preimmunized either with
the native W144, A141, A142, or A144 peptides in CFA
and then challenged with the encephalitogenic PLP 139–
151 to induce EAE. As shown in Fig. 4, preimmunization
with A144 protected mice from the development of EAE.
In contrast, preimmunization with A142 did not show sig-
nificant protection and A141 showed slight inhibition of
disease, which was not significant. However, in other ex-
periments preimmunization with A141 and A142 acceler-
ated the day of onset and enhanced severity of disease (data
not shown). These data suggest that preimmunization with
A144 probably leads to the expansion of the A144-reactive
protective repertoire that inhibited the disease induced
with the native peptide.
Besides expanding a protective T cell repertoire, several
other mechanisms could explain protective effects of pre-
immunization with A144 peptide; for example, A144 could
mediate MHC blockade or antagonize PLP 139–151-spe-
cific Th1 cells and inhibit generation of an encephalito-
genic T cell repertoire. A144 peptide does not have signifi-
cantly higher binding for I-As than the native PLP 139–151
peptide. Furthermore, we coimmunized mice with A144 plus
PLP 139–151 peptides and tested the lymph node cells for
their ability to proliferate to PLP 139–151 and A144 pep-
tides. Coimmunization of mice with A144 plus PLP 139–
151 does not inhibit the generation of PLP 139–151-spe-
cific W144-reactive T cells (Fig. 5), suggesting that A144
does not mediate MHC blockade, thereby inhibiting the
generation of W144-reactive cells. We have undertaken a
detailed analysis to test whether A144 can act as a TCR an-
tagonist of the PLP 139–151-specific Th1 repertoire. Our
studies showed that the A144 does not antagonize PLP
139–151-specific T cell clones or PLP 139–151-specific T
cell lines (17). To study whether A144 immunization ex-
panded the protective Th2/Th0 repertoire, we immunized
SJL mice with PLP 139–151 or A144 in CFA and tested the
lymph node cells from these mice for proliferation and cy-
tokine production by in vitro activation with native PLP
139–151 and A144 peptide (Table 2). The lymph node
cells from PLP 139–151 immunized mice proliferated spe-
cifically to the native peptide and produced large amounts
of Th1 cytokines, particularly IL–2 and IFN-g. Consistent
with the Th1 clone data, PLP 139–151-immunized lymph
node cells did not show a significant proliferation or pro-
duce significant cytokines in response to A144 peptide. In
contrast, the lymph node cells from the A144-immunized
mice proliferated equally well to both the A144 and PLP
139–151 peptides as has been detected with the Th2/Th0
clones. The lymph node cells from A144-immunized mice
when activated with A144 produced little IFN-g, but pro-
duced large amounts of IL-10. We could not detect signifi-
cant amounts of IL-4 in the primary lymph node cultures
after activation with A144, but small amounts of IL-4 were
detected after activation with the native peptide. These
data are consistent with the observation that in contrast
with the native peptide that induces Th1 cells, immuniza-
tion with A144 even in CFA activates the alternate PLP
139–151 cross-reactive Th2/Th0 repertoire, which may be
responsible for protection against EAE. The data obtained
with immunization with the A144 peptide are similar in
many ways to those obtained with the Q144 peptide in
which we have seen that preimmunization with Q144 pro-
tects mice for the development of EAE and lymph node
cells of these mice produce IL-10 upon in vitro activation
(21). However, after cloning these cells in vitro, IL-4–pro-
ducing Th2 clones were uncovered (21). It is relatively dif-
ficult to detect IL-4 in primary lymph node cultures, which
may be due to very low levels of IL-4, or to its consump-
tion or inhibition by other cytokines.
Discussion
We have examined the structural requirements for acti-
vation of PLP 139–151-specific Th1 and Th2 clones. Al-
though the autopathogenic Th1 clones recognize W144 as
Figure 4. Preimmunization
with A144 ameliorates EAE. An-
imals were preimmunized with
the native peptide W144 (open
squares), A141 (open triangle),
A142 (open circle), or A144 (closed
circle) and 7 d later reimmunized
with the native PLP peptide
139–151 and assessed daily for
signs of clinical disease.
Figure 5. Proliferative response of lymph node cells of SJL mice im-
munized with 100 mg/mouse of PLP 139–151, A144, or a mixture of
PLP 139–151 plus A144 peptides in CFA. Lymph node cells were acti-
vated 10 d after immunization with indicated peptides in a 3-d prolifera-
tion assay. Data represent mean CPM in triplicate wells.874 Th1 and Th2 Clones Recognize the Same Peptide Differently
the primary and critical TCR contact residue, the PLP 139–
151-specific Th2 clones do not require this residue for acti-
vation. Instead, the Th2 clones have shifted their emphasis
to L141/G142 at the NH2-terminal end of the peptide.
Analysis of additional PLP 139–151-reactive Th2/Th0 clones,
generated by immunization with an altered peptide in which
tryptophan was substituted by glutamine at position 144
(21), also showed a similar shift in the critical TCR residues
towards the NH2-terminal end of the peptide. These results
suggest that Th1 and Th2 clones specific for the same pep-
tide in the autoreactive repertoire can be dependent on dif-
ferent residues in the peptide for their induction and activa-
tion and that T cell differentiation may be influenced by
the recognition of specific residues in an autoantigenic pep-
tide.
The data presented here raise an important issue as to
why Th1 and Th2 clones specific for PLP 139–151 should
recognize different parts of the same peptide. It has already
been shown that T cells from TCR transgenic mice of
identical specificity can be driven to become either Th1 or
Th2 cells, depending upon the cytokines used in the pri-
mary activation culture (23, 24) or the dose of antigen (25,
26) used in initial activation. Although cytokine milieu is the
most dominant factor in determining the outcome of T cell
differentiation (27), studies with antigen dose would suggest
that strength of initial signal generated by the ligation of
TCRs would also influence the outcome. Low dose antigen
(lower T cell activation/lower strength of signal) generated
Th2 cells; relatively higher amounts of antigen (presumably
giving a higher strength of signal) promoted differentiation
of T cells in the Th1 direction; further higher concentra-
tion led to the generation of Th2 cells (25, 26). Our data
would suggest that in vivo, the PLP 139–151-specific T
cell repertoire consists of at least two populations of T cells
using either W144 or L141/G142 as the major contact res-
idues. When these populations are exposed to PLP 139–
151 under conventional immunizing conditions, the W144-
dependent cells become dominant in the expanded repertoire.
This may be because precursor cells of this type are present
at higher frequency in the naive PLP 139–151-specific
pool, or because W144-dependent TCRs have a higher
avidity for antigen–MHC complex. In the latter case, such
cells will receive a stronger signal at all antigen concentra-
tions, leading to greater growth than the L141/G142-
dependent cells and also tending to promote differentiation
along a Th1 pathway. This may explain why immunization
with the native PLP 139–151 routinely induces W144-spe-
cific Th1 clones when the cells are reactivated by the native
peptide (13, 18–20). In the presence of anti–B7-1 antibody,
the W144 costimulation-dependent Th1 clones are presum-
ably not activated, allowing the growth of L141/G142-rec-
ognizing cells. These L141/G142 Th2 may belong to a
memory population, stimulated in vivo by autoantigen or
cross-reactive ligand and may, therefore, have a less strin-
gent requirement for costimulation. It has been shown that
memory cells that produce TGF-b or Th2 cytokines may
play a critical role in maintenance of peripheral tolerance to
self-antigens (28).
We (21) and others (29, 30) have recently shown that al-
tered peptides generated by the substitution of TCR con-
tact residues selectively affect T cell differentiation and alter
cytokine balance. In our studies, replacement of the pri-
mary contact residue of tryptophan with glutamine at posi-
tion 144 in the PLP 139–151 peptide leads to the induction
of T cells that have two important properties: (a) the clones
are of Th0/Th2 phenotype and (b) besides recognizing
Q144, they also recognize the native PLP 139–151 pep-
tide. Although it is possible that Q144-specific T cell
clones could recognize Q at position 144 as the primary
contact residue in the altered peptide and be Q144-spe-
cific, in that case the T cells would not cross-react with the
native peptide. How does a single residue substitution in
the primary T cell contact point of the encephalitogenic
PLP peptide generate Th2/Th0 clones that cross-react with
the native peptide? Our data on the shift of primary contact
residue from W144 to L141/G142 begins to explain this
data. The immunization with Q144 altered peptide does
not activate W144-reactive Th1 cells, but promotes the
Table 2. Proliferation and Cytokine Production by the Lymph Nodes Cells of Mice Immunized with PLP 139–151 and A144 Peptide
Cytokine production
Immunization Activation Proliferation IL-2 IFN-g IL-4 IL-10
D cpm D pg/ml
PLP 139–151 PLP 139–151 93,040 1,820 2,740 110 ,80
A144 4,490 ,80 ,80 ,80 ,80
A144 A144 15,620 ,80 180 90 1,050
PLP 139–151 16,430 ,80 ,80 180 ,80
Groups of SJL mice were immunized with PLP 139–151 or A144 peptide (100 mg of peptide/mouse) in CFA. Lymph node cells were collected 10
d later and activated in vitro with four different dilutions (0.1–100 mg/ml) of PLP 139–151 or A144 peptides. Maximal proliferation and cytokine
production was obtained at an antigen concentration of 10 mg/ml and this data is shown. Culture supernatants were collected 40 h after activation
and tested by cytokine ELISA. Proliferation was assessed after 48 h as described.875 Prabhu Das et al.
growth of L141/G142-reactive cells. Because of this
epitope shift, the cells are of a Th2 phenotype, but main-
tain cross-reactivity with the native peptide.
The PLP 139–151-specific Th2 clones that we have re-
ported here were generated after the administration with
anti–B7-1 antibody in vivo, and one might argue that epi-
tope shift is not unique to the PLP 139–151-specific Th2
cells but is due to the presence of anti–B7-1 antibody. Two
lines of evidence argue against this hypothesis: (a) a PLP
139–151-specific Th1 clone generated in parallel by anti–
B7-1 antibody administration in vivo used W144 and not
L141/G142 as the primary TCR contact residue (data not
shown), and (b) immunization with the altered peptides in
which the primary TCR contact residue was substituted
induces PLP 139–151-reactive Th2 cells with a similar shift
in the primary contact residues, further suggesting that
epitope shift is not specifically due to the administration of
anti–B7-1 antibody in vivo.
Some studies have shown that Th2 cells are not sufficient
to protect from autoimmune disease (16). Khoruts et al.
(14) and Katz et al. (31) reported that Th1 populations ef-
fectively transferred autoimmunity, whereas Th2 did not.
However, the Th2 did not suppress autoimmunity caused
by Th1. In our previous studies (15, 21), we demonstrated
the Th2 clones studied in detail here and Q144-specific
lines mediated protection from EAE. These cells also have
a shift in their TCR contact residue. Therefore, it is possi-
ble that epitope specificity together with Th2 cytokines
may be necessary for the protective phenotype. Thus, be-
cause PLP 139–151-specific pathogenic Th1 and protective
Th2 clones differ in their primary TCR contact residue,
this provided us with a unique opportunity to generate
altered peptides that can inhibit pathogenic Th1, selectively
induce protective Th2 clones, and ameliorate autoim-
munity.
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